CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
In a recent CBS News New York interview, Dotmatics VP of Science and Technology, Phil Mounteney, discusses how artificial intelligence is transforming the drug discovery process. AI is helping researchers accelerate timelines, reduce costs, and deliver safer, more effective therapies to market.
By leveraging AI to analyze scientific data generated during early-phase research, Dotmatics enables teams to significantly shorten traditional development cycles for vaccines and personalized medicine. The AI models used are developed and stored internally, ensuring data privacy while fostering innovation at scale.
Dotmatics is supporting the healthcare industry in moving faster and smarter toward breakthrough cures.
Related
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
Dotmatics on KSNV: The Role of AI in Accelerating the Discovery of Life-Saving Medicines
In a KSNV interview, Phil Mounteney, VP of Science and Technology at Dotmatics, discusses how their AI-ready platform is revolutionizing drug discovery by enabling scientists to develop life-saving medicines more quickly and cost-effectively, potentially reducing drug development timelines from ten years to just a few and advancing personalized medicine.